

To,
The Manager,
Corporate Compliance Department
BSE Limited
PhirozeJeejeebhoy Tower
Dalal Street
Mumbai-400001

Date: 29/06/2021

Scrip Code: (BSE-542934)

Sub:-Outcome of Board Meeting held on Tuesday, 29th June, 2021 pursuant to the Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 ("Listing Regulation").

Dear Sir/Madam,


The Board of Directors of the Company in their meeting held on 29th June, 2021 at Registered Office of Company viz. 323-F, Bhagat Bhuvan, Dr. Ambedkar Road, Matunga East, Mumbai-400019, which commenced at 05:00 pm and concluded at 06:00 pm inter alia, approved the Audited Financial Result of the Company for the year ended on 31st March, 2021 along with the statement of Assets & Liabilities as on that date and took on records Auditor's Report thereon furnished by the Statutory Auditor of the Company in compliance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015.

In accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015 and Company's code of conduct for prohibition of Insider Trading, The "Trading Window" for trading in the shares of the Company will open after 48 hours from Announcement of Financial Statement for the Directors and Key Managerial Personnel/Designated Employees/ Connected person of the Company as defined in the code of conduct for prohibition of Insider Trading of the Company.

Kindly take the above on record and inform all those concerned accordingly.

Yours Sincerely,

FOR CHANDRA BHAGAT PHARMA LIMITED



HEMANT C BHAGAT

CHAIRMAN & MANAGING DIRECTOR
DIN: 00233530



A Y & COMPANY
404, Fourth Floor, ARG Corporate Park
Gopal Bari, Ajmer Road, Jaipur (Raj.)
TEL NO. - +91-9649687300
Email: info@aycompany.co.in

Auditor's report on Annual Financial Results of Chandra Bhagat Pharma Limited for the year ended March 31, 2021 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

**The Board of Directors of
Chandra Bhagat Pharma Limited**

Opinion

We have audited the accompanying statement of Annual Financial Results ("the Statement") of Chandra Bhagat Pharma Limited (hereinafter referred to as "the Company") for the year ended March 31, 2021, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid year to date annual financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended in this regard; and;
- (ii) give a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of the net profit of the Company for the year ended March 31, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Annual Financial Results section of our report. We are independent of the Company in accordance with the code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the annual financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the annual financial results.





A Y & COMPANY

404, Fourth Floor, ARG Corporate Park
Gopal Bari, Ajmer Road, Jaipur (Raj.)
TEL NO. - +91-9649687300
Email: info@aycompany.co.in

Management's and Board of Directors' Responsibilities for the Annual Financial Results

These annual financial results have been prepared on the basis of the financial statements. The Company's Management and the Board of Directors are responsible for the preparation and presentation of these annual financial results that give a true and fair view of the net profit/loss in accordance with the recognition and measurement principles laid down in Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act; safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error

In preparing the annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.





A Y & COMPANY

404, Fourth Floor, ARG Corporate Park
Gopal Bari, Ajmer Road, Jaipur (Raj.)
TEL NO. - +91-9649687300
Email: info@aycompany.co.in

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

- During the Financial year 2020-21, the company has Approximately to 87.30% of its total turnover from Top Five Customers only which are subject to third party confirmation.
- During the Financial year 2020-21, the Company has not been regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income-Tax, Goods & Service Tax and any other statutory dues as well as returns with respective authorities.
- As on March 31, 2021 the company has outstanding Unsecured Loan which has been availed from Directors, Relatives from Directors, Shareholders & Others.
- During the year 2020-21, the company has not been regular in repayment of loans/Installments due to Banks & other financial Institutions.
- During the Previous Financial Year 2019-20, the company has given Advance for Raw Material Purchase to its suppliers but the same are still remains unsettled as on March 31, 2021.





A Y & COMPANY

404, Fourth Floor, ARG Corporate Park

Gopal Bari, Ajmer Road, Jaipur (Raj.)

TEL NO. - +91-9649687300

Email: info@aycompany.co.in

- The annual financial results include the results for the half year ended March 31, 2021 being the balancing figures between the audited figures of the full financial year and the published unaudited year to date figures up to the First Half Year of the current financial year. The figures up to the end of the first Half Year of the respective financial year are only reviewed and not subjected to audit.

For, M/S A Y & CO
Chartered Accountants
F.R.N: - 020829C



ARPIT GUPTA

Partner

M.NO.-421544

UDIN - 21421544AAAABH1316

Date: June 29, 2021

Place: Mumbai

CHANDRA BHAGAT PHARMA LIMITED

CIN No: U24230MH2003PLC139534

323-F BHAGAT BHUVAN DR.AMBEDKAR ROAD MATUNGA (EAST) - MUMBAI MAHARASHTRA- 400019 Email : compliancecbcb@gmail.com

Statement of Audited Financial Results for the half year and year ended on March 31, 2021 Pursuant to regulation 33 of SEBI (LODR) Regulation, 2015

	Particulars	Six Months Ended on 31/03/2021 (Amount in Rs.)	Six Months Ended on 30/09/2020 (Amount in Rs.)	Year to date figures for year ended 31/03/2021 (Amount in Rs.)	Year to date figures for year ended 31/03/2020 (Amount in Rs.)
		Audited	Unaudited	Audited	Audited
	INCOME FROM OPERATIONS				
I	Revenue from Operations	483,309,080	223,644,110	706,953,190	939,809,030
II	Other Income	4,582,926	174,621	4,757,547	4,445,102
III	Total Income from Operations	487,892,006	223,818,731	711,710,737	944,254,132
IV	EXPENSES				
	Cost of Material Consumed	91,335,398	-	91,335,398	21,867,097
	Purchase of Stock in Trade	248,029,068	198,458,263	446,487,331	840,702,927
	Change in inventories of Finished Goods, WIP & Stock in Trade	72,121,840	(12,540,662)	59,581,178	(4,581,882)
	Employee benefit expenses	14,454,339	5,930,786	20,385,125	24,408,913
	Finance Cost	18,617,947	16,217,692	34,835,639	30,603,661
	Depreciation & Amortization Expense	230,563	104,126	334,689	319,170
	Other Expenses	40,727,999	15,234,630	55,962,629	26,710,208
	Total expenses (IV)	485,517,154	223,404,835	708,921,989	940,030,094
V	Profit/(loss) before Exceptional Items & Tax (III-IV)	2,374,852	413,896	2,788,748	4,224,038
VI	Exceptional Items	-	-	-	-
VII	Profit/(loss) before tax (VIII-IX)	2,374,852	413,896	2,788,748	4,224,038
X	Tax Expenses				
	1 Current Tax	689,675	105,639	795,314	959,724
	2 Deferred Tax	131,392	(36,759)	94,633	116,623
	Total Tax Expenses (XI)	821,067	68,880	889,947	1,076,347
XI	Profit/(Loss) after Tax (X-XI)	1,553,785	345,016	1,898,801	3,147,691
XII	Paid up Equity Share Capital	75,450,560	75,450,560	75,450,560	75,450,560
XIII	Reserves & Surplus	183,337,515	181,783,730	183,337,515	181,438,714
XIV	Earnings per equity share				
	(1) Basic	0.21	0.05	0.25	0.55
	(2) Diluted	0.21	0.05	0.25	0.55

For Chandra Bhagat Pharma Limited

Hemant C Bhagat
Chairman Cum Managing Director
DIN : 00233530

Place : Mumbai
Date : June 29, 2021



CHANDRA BHAGAT PHARMA LIMITED

CIN No: U24230MH2003PLC139534

323-F BHAGAT BHUVAN DR.AMBEDKAR ROAD MATUNGA (EAST) - MUMBAI MAHARASHTRA- 400019 Email :
compliancecb@gmail.com

Statement of Assets & Liabilities as at March 31, 2021

Particulars	As at March 31, 2021 (Amount in Rs.)	As at March 31, 2020 (Amount in Rs.)
	Unaudited	Audited
I. Equity and Liabilities		
Shareholders Fund		
Share Capital	75,450,560	75,450,560
Reserves & Surplus	183,337,515	181,438,714
	258,788,075	256,889,274
Non-current liabilities		
Long Term Borrowings	94,511,556	108,868,474
Deferred tax liabilities (Net)	96,754	2,121
Other Long Term Liabilities	35,705,526	40,919,440
	130,313,836	149,790,035
Current liabilities		
Short Term Borrowings	156,339,235	166,174,068
Trade payables		
(a) total outstanding dues of micro and small enterprises	-	-
(b) total outstanding dues other than micro and small enterprises	128,536,518	124,855,933
Other current liabilities	43,039,950	48,726,496
Short term Provisions	795,314	959,724
	328,711,017	340,716,221
Total	717,812,928	747,395,530
II. Assets		
Non-current assets		
Fixed assets		
Tangible Assets	4,227,040	4,358,285
Capital WIP	-	-
Intangible Assets	-	-
Other Non Current Assets	13,486,349	14,351,777
Deferred Tax Assets (Net)	-	-
	17,713,389	18,710,062
Current Assets		
Investments	4,003,469	7,456,644
Inventories	351,391,739	439,026,059
Trade Receivables	154,181,542	140,296,460
Cash & Bank Balances	24,208,229	524,376
Short Term loans & advances	163,407,247	136,984,323
Other current Assets	2,907,313	4,397,606
	700,099,539	728,685,468
Total	717,812,928	747,395,530

Notes:-

1. The above Audited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on June 29, 2021
2. The Statutory Auditors of the Company have carried out the Audit of these Results
3. There are no investor complaints received/pending as on March 31, 2021
4. Previous year/s/ period figures have been regrouped/ reclassified/ restated, wherever necessary to confirm to classification of current year/period.

For Chandra Bhagat Pharma Limited

Hemant C Bhagat
Chairman Cum Managing Director
DIN : 00233530

Place : Mumbai
Date : June 29, 2021



Chandra Bhagat Pharma Limited
(Formerly Known as Chandra Bhagat Pharma Private Limited)
CIN No: U24230MH2003PLC139534
Cash Flow Statement for the period ended March 31, 2021

Cash flow statement as at	31 March 2021 (Amount in Rs.)	31 March 2020 (Amount in Rs.)
Cash flow from operating activities		
Net Profit before tax and extraordinary items	2,788,748	4,224,038
Non-Cash adjustment to reconcile profit before tax to net cash flows		
Depreciation	334,689	319,170
Interest Received	(523,398)	(3,974,784)
Finance Cost	34,835,639	30,603,661
Operating profit before Working Capital changes	37,435,678	31,172,085
Change in Working Capital	40,428,988	(105,302,326)
Increase/(Decrease) in Trade Payables	3,680,585	(172,154,329)
Increase/(Decrease) in Other current Liabilities	(5,686,546)	(16,044,830)
Decrease/(Increase) in Inventories	87,634,320	110,006
Decrease/(Increase) in Trade receivables	(13,885,082)	122,681,980
Decrease/(Increase) in Short term Loans and advances	(26,422,924)	(79,775,001)
Decrease/(Increase) in Other Current Assets	1,490,293	4,041,789
Increase/(Decrease) in Short term Borrowings	(9,834,833)	2,956,685
Decrease/(Increase) in Investments	3,453,175	32,881,374
Cash generated from operations	77,864,666	(74,130,241)
Income Tax(Paid)/ Refund	(959,724)	-
Net Cash flow from / (used in) Operating activities (A)	76,904,942	(74,130,241)
Cash Flow from/(used in) Investing Activities		
Purchase of Fixed Assets	(203,444)	(38,078)
Interest received	523,398	3,974,784
(Increase)/Decrease in Other Non Current Assets	865,428	(3,434,777)
Net Cash (used in) investing activities (B)	1,185,382	501,929
Cash Flow from/ (used in) Financing Activities		
Finance Cost	(34,835,639)	(30,603,661)
Proceeds from issue of Share Capital	-	21,820,000
Proceeds from Security Premium	-	87,460,000
Proceeds/ (Repayment) of Long term Borrowings	(19,570,832)	(9,303,490)
Net Cash flow from / (used in) financing activities (C)	(54,406,471)	69,372,849
Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	23,683,853	(4,255,463)
Cash and Cash Equivalents at the beginning of the year	524,376	4,779,839
Cash and Cash Equivalents at the end of the year	24,208,229	524,376

For Chandra Bhagat Pharma Limited

Hemant C Bhagat
Chairman Cum Managing Director
DIN : 00233530

Place : Mumbai
Date : June 29, 2021





Chandra Bhagat Pharma Limited

Date: 29.06.2021

To
The Listing Compliance Department
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai-400001

BSE Security Code: 542934

Sub: Sub: Declaration Pursuant to the Regulation 33(3) of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.

Dear Sir/Madam,

Dear Sir/Madam,

I, Hemant C Bhagat, Managing Director of Chandra Bhagat Pharma Limited having it's Registered Office at viz. 323-F, Bhagat Bhuvan, Dr. Ambedkar Road, Matunga East, Mumbai-400019, hereby declares that the statutory Auditors of the Company A Y & Company (FRN: 020829C) has issued an Audit Report with unmodified opinion on Audited Financial Results for the year ended 31st March, 2021.

This deceleration is issued in compliance with the Regulation 33(3) of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 as amended vide circular CIR/CFD/CMD/56/2016 dated 27th May, 2016.

Kindly take above information(s) / document(s) on your record and oblige.

Thanking You,

Yours faithfully,

FOR CHANDRA BHAGAT PHARMA LIMITED

HEMANT C BHAGAT

CHAIRMAN & MANAGING DIRECTOR
DIN: 00233530